Price$3.64-0.15 (-3.96%)
01:15 PM05:15 PM
News · 26 weeks37+100%
2025-12-142026-06-07
Mix1790d
- SEC Filings10(59%)
- Other7(41%)
Latest news
25 items- SECSEC Form SC 14D9 filed by Lisata Therapeutics Inc.SC 14D9 - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- PRLisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction valued Lisata at a significant premium to the historical market price of Lisata common stock prior to the announcement of the proposed transaction and provides potential additional upside if the specified milestones are achieved Lisata Board of Directors unanimously recommends stockholders to tender their shares The transaction is expected to close in the third quarter of 2026, subject to
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form 10-Q filed by Lisata Therapeutics Inc.10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Lisata Therapeutics Inc.10-K/A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECSEC Form 8-K filed by Lisata Therapeutics Inc.8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECSEC Form 10-K filed by Lisata Therapeutics Inc.10-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the transaction and recommends that stockholders tender their shares Transaction expected to close in the second quarter of 2026 BASKING RIDGE, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a definitive agreement to be acquired by Kuva La
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideBASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. ("Qilu"). The original agreement, negotiated and implemented with CEND Therapeutics and assumed by Lisata as part of its acquisition of CEND Therapeutics in 2022, granted Qilu exclusive rights to develop and commercialize certepetide, Lisata's proprietary iRGD cyclic peptide product
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
LSTA FAQ
4 questionsWhere does LSTA stock trade?
Lisata Therapeutics Inc. (LSTA) is listed on NASDAQ.What sector and industry is LSTA in?
Lisata Therapeutics Inc. operates in the Health Care sector, Misc Health and Biotechnology Services industry.What companies are similar to LSTA?
Notable peers in the same industry include DVA (DaVita Inc.), FMS (Fresenius Medical Care AG), SHC (Sotera Health Company), PGNY (Progyny Inc.), AGL (agilon health inc.). Compare LSTA side-by-side with any of them on Quantisnow.How can I track LSTA on Quantisnow?
Quantisnow aggregates Lisata Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LSTA to receive live email and push alerts on every new disclosure.